Drugs / IMA201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03247309 | Dec 2018 → Apr 2023 | cancer | Immatics US, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-17 | Immatics Biotechnologies GmbH | Results Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs immatics.com ↗
Clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine® T cells. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-17 | Immatics Biotechnologies GmbH | Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs immatics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03247309 ↗ |
| Route | Intravenous | “One dose of IMA201 product will be infused intravenously.” NCT03247309 ↗ |